Jazz Pharmaceuticals JAZZ Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's stock-based comp?
- Jazz Pharmaceuticals (JAZZ) reported stock-based comp of $2.21M in Q4 2025.
- How has Jazz Pharmaceuticals's stock-based comp changed year-over-year?
- Jazz Pharmaceuticals's stock-based comp decreased by 18.7% year-over-year, from $2.72M to $2.21M.
- What is the long-term trend for Jazz Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's stock-based comp has grown at a -18.3% compound annual growth rate (CAGR), from $19.91M to $8.86M.
- What does stock-based comp mean?
- The dollar value of stock-based compensation that cannot be deducted for tax purposes.
- How do you interpret stock-based comp?
- Lower values are preferred as they indicate that a higher portion of compensation is tax-deductible, reducing the effective tax rate.
- How does stock-based comp compare across companies?
- Commonly disclosed in the tax reconciliation footnotes of public companies with significant equity compensation.